Wednesday, March 05, 2025 | 03:31 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Shilpa Medicare surges 13% after receiving EIR from USFDA

The stock surged 13% to Rs 434 on the BSE in morning trade after the company said it has received EIR from the US health regulator for it's both facilities located at Raichur, Karnataka.

v
Premium

Pharma Stocks, Sun Pharma, Cadila, Cipla

SI Reporter Mumbai
Shares of Shilpa Medicare have surged by 13% to Rs 434 per share on the BSE in morning trade after the company said that it has received Establishment Inspection Report (EIR) from the US health regulator for both of its facilities located at Raichur, Karnataka.

“Our both active pharmaceutical ingredient (API) manufacturing facilities located at Raichur, Karnataka, received EIR from the US Food and Drug Administration (US FDA),” Shilpa Medicare said in a regulatory filing.

This inspection was carried out between 16th and 19th January, 2018. The inspection has now been closed by USFDA, it added.

On

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in